<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Determine the influence of urapidil on mean lumbar cerebrospinal fluid pressure (CSFP), mean arterial pressure (MAP), mean central venous pressure (CVP) and heart rate (HR) in awake humans without any evidence of cerebral or <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN: Open, single-dose volunteer study </plain></SENT>
<SENT sid="2" pm="."><plain>INTERVENTIONS: CSFP was measured via a spinal needle after i.v. injection of a single dose of 0.2 mg kg-1 urapidil in six volunteers (2 female, 4 male) </plain></SENT>
<SENT sid="3" pm="."><plain>MEASUREMENTS AND RESULTS: After administration of urapidil, CSFP increased from 7 +/- 1 mmHg to 10 +/- 1 mmHg (p &lt; 0.05), MAP decreased from 88 +/- 7 mmHg to 74 +/- 5 mmHg (p &lt; 0.05), CPP decreased from 81 +/- 7 mmHg to 64 +/- 5 mmHg (p &lt; 0.05) and CVP decreased from 0 +/- 1 mmHg to -3 +/- 1 mmHg (p &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>CONCLUSION: Our data suggest that in humans with presumed <z:mpath ids='MPATH_458'>normal</z:mpath> intracranial compliance the administration of urapidil causes a small but statistically significant increase in CSFP due to a parallel decrease in MAP </plain></SENT>
</text></document>